key: cord-0852876-guovhrad authors: Sahu, Kamal Kant; Siddiqui, Ahmad Daniyal; Rezaei, Nima; Cerny, Jan title: Challenges for management of immune thrombocytopenia during COVID‐19 pandemic date: 2020-07-11 journal: J Med Virol DOI: 10.1002/jmv.26251 sha: 144b0a77e14629719a63cada094e3e86805f061a doc_id: 852876 cord_uid: guovhrad It is almost six months since novel Coronavirus disease 2019 (COVID-19) started as a local outbreak in Wuhan, China(1) For hematologists and patients suffering from hematological disorders, the COVID-19 pandemic has brought challenges with regards to the diagnosis, treatment, follow-up, office visits, and so on. (2,3) We hereby discuss the current challenges for management of immune thrombocytopenia (ITP) during COVID-19 pandemic, based on our practical experience and interim expert recommendations suggested by the hematology societies. This article is protected by copyright. All rights reserved. It is almost 6 months since novel coronavirus disease 2019 started as a local outbreak in Wuhan, China 1 For hematologists and patients suffering from hematological disorders, the COVID-19 pandemic has brought challenges with regard to the diagnosis, treatment, follow-up, office visits, and so on. 2, 3 We hereby discuss the current challenges for management of immune thrombocytopenia (ITP) during COVID-19 pandemic, based on our practical experience and interim expert recommendations suggested by the hematology societies. Thrombocytopenia, in general, is one of the very commonly encountered laboratory anomalies in hematological practice. It is a challenging entity because of multiple reasons which can interplay to cause thrombocytopenia. Thrombocytopenia, and lymphopenia, has been found as common hematological abnormalities in patients with COVID-19, which has also been shown to be an indicator of poor outcome and survival. 4, 5 The prevalence of thrombocytopenia is extremely variable. Huang et al noted COVID-19 non-survivors (20%) to be more thrombocytopenic than survivors (1%). 6 In most COVID-19 cases of thrombocytopenia, the platelet count does not fall below 100 × 10 9 /L. Severe degree of thrombocytopenia (<20 × 10 9 /L, or a sudden drop >50% over 24-48 hours) narrows down the differentials to ITP, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, microangiopathic hemolytic anemia, heparin induced thrombocytopenia, or disseminated intravascular coagulation. 7, 8 But before considering the diagnosis of ITP, it is important to evaluate patients with other treatable causes of thrombocytopenia. 7, 9 The approach to ITP is based on the clinical history, systemic examination, and a detailed hematological work up including a complete blood count, and peripheral smear examination. It is recommended to test patients for HCV and HIV to rule out this viral mediated thrombocytopenia. Guidelines do not recommend bone marrow examination in cases with isolated thrombocytopenia unless there is a concern for aplastic anemia. leukemia, or myelodysplastic syndrome. 10 for complete recovery. 15 The consensus is that if required, non-immunosuppressant treatment modalities should be considered above the immunosuppressant treatment strategies, while managing ITP during the COVID-19 pandemic. The commonly used non-immunosuppressant is IVIG and TPO analogs like romiplostim and eltrombopag. Both ASH and BSH have given the interim recommendations for managing patients with ITP in COVID-19 (Table 1) . BSH precisely mentions about the differential approach to acute ITP in COVID-19 positive and COVID-19 negative patients. BSH recommends considering steroids over thrombopoietin receptor agonists (TPO-RAs) in COVID-19 positive cases and using TPO-RAs (off label) as the first line in COVID-19 negative patients. COVID-19 positive patients are at increased risk of the thromboembolic phenomenon and hence steroids are preferred over TPO agents. Use of steroids and TPO-RAs is based on the risk of increased mortality and superadded infection associated with steroids (in high doses) versus increased thrombotic potential while using TPO-RAs. 6 We believe that every patient with ITP brings his or her own challenge and due to lack of enough evidence, management should be based on the combination of available data, additional experience, and interim recommendations given by hematology societies higher doses (>40 mg methylprednisolone/day). Hence, the BSH recommended that steroid dose and duration should be kept to the minimum with an initial dose of 20 mg daily followed by a tapering trial after 2 weeks. Both BSH and ASH recommend using IVIG as a bridging therapy for dangerously low platelet counts of less than 10 to 30 × 10 9 /L, while waiting for the response of steroids or TPO-RAs. The use of platelet transfusion should be restricted only for major bleeding. Unlike BSH that expressed its concerns over thrombotic sideeffects of TPO agents, ASH suggests that those chronic ITP patients with newly identified COVID-19, who are already on TPO agents in the case of relapse to either increase the dose or to add a second TPO agent. 9 F I G U R E 1 Descriptive figure suggesting the broader categories of scenarios possible in a patient with coronavirus disease 2019 (COVID-19). ITP, immune thrombocytopenia This category includes patients who have newly detected or relapsed chronic ITP without any COVID-19 related concerns or were found to be COVID-19 negative upon testing. BSH recommends TPO-RAs (off label) as the first line over steroids. The idea of not using steroids in COVID-19 negative patients is to keep their immune system active against acquiring COVID-19. 7 The challenge of TPO-RAs would be a delayed onset of action (10-14 days) that might require using IVIG or platelet transfusions as needed. • Patients on corticosteroids ≥20 mg/day (0.5 mg/kg), prednisolone (or equivalent) for more than 4 weeks. • Patients on corticosteroid dose of ≥5 mg/day prednisolone (or equivalent) for more than 4 weeks AND at least one other immunosuppressive medication or rituximab within the last 1 year. 16 • Patients taking a combination of two immunosuppressants, including rituximab within the last 12 months AND an additional co-morbidity. Patients should be encouraged to utilize the resources like telemedicine to reach out to their respective ITP clinics for immediate questions regarding their disease. Every attempt should be made to avoid unnecessary hospital visits and educating patients with proper resources could be a key factor to reduce their anxiety and motivate Latest updates on COVID-2019: a changing paradigm shift From hematologist's desk: the effect of COVID-19 on the blood system Managing sickle cell patients with COVID-19 infection: the need to pool our collective experience A review of cardiac manifestations and predictors of outcome in patients with COVID-19. Heart Lung Clinical characteristics of coronavirus disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Immune thrombocytopenia as a presenting manifestation of tuberculosis-challenge in resource constraint settings Cortical vein thrombosis in a case of idiopathic thrombocytopenic purpura COVID-19 presenting with immune thrombocytopenia: a case report and review of the literature The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment 3 Description of patient information (based on BSH/ASH) regarding ITP in COVID-19. ASH SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 COVID-19 and ITP-Hematology.org. 2020 Platelet Disorder Support Association-for People with ITP-Home Immune thrombocytopenic purpura in a patient with covid-19 Challenges for management of immune thrombocytopenia during COVID-19 pandemic All authors have seen the manuscript and agree to the content and data. All the authors played a significant role in the paper. The authors declare that there are no conflict of interests. http://orcid.org/0000-0002-0382-6882Jan Cerny http://orcid.org/0000-0002-6602-5505